SinoFresh adds R&D capability

VENICE - SinoFresh HealthCare Inc., a publicly traded company, today acquired SRS International Inc., a research and development firm based in Virginia, in an all-stock deal.

The acquisition will help SinoFresh develop three new medicinal products, two of which are nearly ready to be manufactured, according to David Olund, CEO at SinoFresh.

SRS' expertise in both FDA compliance and medicinal claim support will help make new SinoFresh products more marketable. For example, proper claim support could help SinoFresh market products as disease-treating, rather than symptom-relieving, Olund explained.

Last week, SinoFresh HealthCare Inc. (symbol: SFSH) acquired SinoFresh HealthCare Products Inc., a private company that had been functioning as what Olund calls a “corporate firewall” to protect potential investors from business risk. That transaction marked the end of a two-year rebuilding process that took SinoFresh from $2.5 million in debt on the books to the verge of profitability.

Headquartered in Venice, SinoFresh HealthCare Inc. manufactures and distributes nasal, oral and topical antiseptic germ-killing products.